Revisiting dezocine for opioid use disorder: A narrative review of its potential abuse liability

被引:1
作者
Barr, Gordon A. [1 ,2 ,3 ]
Schmidt, Heath D. [4 ,5 ]
Thakrar, Ashish P. [6 ,7 ]
Kranzler, Henry R. [5 ,8 ]
Liu, Renyu [2 ,9 ]
机构
[1] Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA
[2] Univ Penn, Dept Anesthesiol & Crit Care Med, Perelman Sch Med, Philadelphia, PA 19104 USA
[3] Univ Penn, Dept Psychol, Philadelphia, PA 19104 USA
[4] Univ Penn, Sch Nursing, Dept Biobehav Hlth Sci, Philadelphia, PA 19104 USA
[5] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA
[6] Univ Penn, Perelman Sch Med, Dept Med, Div Gen Internal Med, Philadelphia, PA 19104 USA
[7] Univ Penn, Penn Ctr Addict Med & Policy, Perelman Sch Med, Philadelphia, PA 19104 USA
[8] Crescenz VAMC, Vet Integrated Serv Network 4, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA
[9] Univ Penn, Perelman Sch Med, Dept Neurol, Philadelphia, PA 19104 USA
关键词
biased mu-opioid ligand; dependence; dezocine; drug discrimination; drug self-administration; opioid use disorder; RESPIRATORY DEPRESSION; CELLS;
D O I
10.1111/cns.70034
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Aims: Opioid use disorder (OUD) remains a serious public health problem. Opioid maintenance treatment is effective but under-utilized, hard to access under existing federal regulations, and, once patients achieve OUD stability, challenging to discontinue. Fewer than 2% of persons with OUD stop using opioids completely. There have been calls from public advocacy groups, governmental agencies, and public health officials for new treatments for OUD. Dezocine, a non-scheduled opioid previously used in the United States and currently widely prescribed in China for pain management, could be a candidate for a novel OUD treatment medication in the U.S. Nonetheless, to date, there have been no reviews of the clinical and preclinical literature detailing dezocine's abuse potential, a key consideration in assessing its clinical utility. Discussion: There are no English language reports of human abuse, dependence, or overdose of dezocine, despite years of extensive clinical use. There are a few case reports of dezocine abuse in the Chinese literature, but there are no reports of overdose deaths. Dezocine is perceived as an opioid and is "liked" by opioid-experienced human and non-human primates, properties that are not dose-dependent and are mitigated by ceiling effects-higher doses do not result in more "liking." There is little withdrawal, spontaneous or precipitated, in humans, monkeys, rats, or mice treated chronically with dezocine alone. However, at some doses, dezocine can precipitate withdrawal in humans and monkeys dependent on other opioids. In rodents, dezocine reduces the severity of morphine withdrawal and the rewarding properties of other opioids. Conclusions: Although dezocine is reinforcing in humans and monkeys with prior or concurrent opioid use within a restricted dose range, there are only a few anecdotal reports of dezocine abuse despite of the long history of use in humans. Given the evidence of dezocine's limited abuse potential, it could be useful both as a treatment for OUD. However, in-depth studies would be required for dezocine to be re-considered for clinical use.
引用
收藏
页数:10
相关论文
共 65 条
  • [1] Comparative study of dezocine, pentazocine and tapentadol on antinociception and physical dependence
    Ahsan, Muhammad Zaeem
    Zhao, Meng-Jing
    Shoaib, Rana Muhammad
    Zhang, Yan
    Wang, Yong-Xiang
    [J]. LIFE SCIENCES, 2021, 285
  • [2] Effects of dexmedetomidine combined with dezocine on T lymphocytes, NK cells and cognitive function in elderly patients with gastrointestinal cancer after radical surgery
    Ai, Zijian
    [J]. CELLULAR AND MOLECULAR BIOLOGY, 2023, 69 (10) : 56 - 62
  • [3] Identifying gender differences in risk profiles and in opioid treatment outcomes in Los Angeles County
    Amaro, Hortensia
    Kong, Yinfei
    Marsh, Jeanne C.
    Khachikian, Tenie
    Guerrero, Erick G.
    [J]. EVALUATION AND PROGRAM PLANNING, 2023, 97
  • [4] Polypharmacy Among Patients With Major Depressive Disorder and Co-occurring Substance Use Disorders in a Psychiatric Hospital Setting Prevalence and Risk Factors
    Benz, Madeline B.
    Epstein-Lubow, Gary
    Weinstock, Lauren M.
    Gaudiano, Brandon A.
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2023, 43 (03) : 273 - 277
  • [5] Management of opioid use disorder in the USA: present status and future directions
    Blanco, Carlos
    Volkow, Nora D.
    [J]. LANCET, 2019, 393 (10182) : 1760 - 1772
  • [6] "I'll Be Back": The Resurrection of Dezocine
    Childers, Wayne E.
    Abou-Gharbia, Magid A.
    [J]. ACS MEDICINAL CHEMISTRY LETTERS, 2021, 12 (06): : 961 - 968
  • [7] Comparison of the analgesic effect of dezocine and esketamine in combination with sufentanil respectively after laparoscopic cholecystectomy: a prospective randomized controlled study
    Deng, Boran
    Wang, Dingding
    Xie, Zifeng
    Wang, Yongqin
    Huang, Li
    Jiang, Manlin
    Shen, Tu
    [J]. BMC ANESTHESIOLOGY, 2024, 24 (01)
  • [8] Application Effect of Dexmedetomidine and Dezocine in Patients Undergoing Lung Cancer Surgery under General Anesthesia and Analysis of Their Roles in Recovery Time and Cognitive Function
    Ding, Jie
    Zhu, Mengqi
    Lv, Hu
    Zhang, Jun
    Chen, Wei
    [J]. COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE, 2022, 2022
  • [9] FORTNIGHTLY REVIEW - METHADONE-MAINTENANCE TREATMENT IN OPIATE DEPENDENCE - A REVIEW
    FARRELL, M
    WARD, J
    MATTICK, R
    HALL, W
    STIMSON, GV
    JARLAIS, DD
    GOSSOP, M
    STRANG, J
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1994, 309 (6960): : 997 - 1001
  • [10] Effect of Dezocine on IL-12 and IL-10 secretion and lymphocyte activation by culturing dendritic cells from human umbilical cord blood
    Feng, Chang
    Feng, Man
    Jiao, Ran
    Liu, Dongyi
    Jin, Yanwu
    Zhao, Xin
    Xiao, Ruixue
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2017, 796 : 110 - 114